

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (Cancelled)

Claim 2. (Currently amended) The method according to ~~Claim 1~~ Claim 14 wherein the male subject has serum testosterone levels less than 450 ng/dL.

Claim 3. (Currently amended) The method according to ~~Claim 1~~ Claim 14 wherein the male subject's waist circumference is greater than 102 cm.

Claim 4. (Currently amended) The method according to ~~Claim 1~~ Claim 14 wherein the effective amount of the first compound ~~of structural formula I, II, III or IV~~ is an amount that reduces serum dihydrotestosterone levels by about 30% or more when administered to the male subject.

Claim 5.-13. (Cancelled)

Claim 14. (New) A method of treating a male subject with metabolic syndrome comprising administration of an effective amount of a first compound selected from the group consisting of:

17 β -(N-tert-butylcarbamoyl)-3-oxo-4-aza-5 α -androst-1-en-3-one;
N-(2,5-bis-trifluoromethyl-phenyl)-3-oxo-4-aza-4-methyl-5 α -androst-1-ene-17 β -carboxamide; and
3-oxo-4-aza-7 β -methyl-16 β -(4-methylphenoxy)-5 α -androst-1-ene; or a pharmaceutically acceptable salt thereof, and an effective amount of a second compound selected from the group consisting of: testosterone, and a testosterone prodrug or a pharmaceutically acceptable salt thereof.

Claim 15. (New) A method of treating a male subject with metabolic syndrome comprising administration of an effective amount of a first compound which is
17 β -(N-tert-butylcarbamoyl)-3-oxo-4-aza-5 α -androst-1-en-3-one;
or a pharmaceutically acceptable salt thereof, and an effective amount of a second compound selected from the group consisting of: testosterone, and a testosterone prodrug or a pharmaceutically acceptable salt thereof.

Claim 16. (New) The method according to Claim 14, wherein the first compound is 3-oxo-4-aza-7 β -methyl-16 β -(methylphenoxy)-5 α -androst-1-ene.